Search research articles
Contact Us
Filters
Showing results (451-460 of 627) with videos related to
Page
of 63
Sort By:
The American Journal of Cardiology
|
July 14, 2022
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)
Rubina Attar, Angie Wu, Daniel Wojdyla, et al.
Journal of Human Hypertension
|
June 5, 2015
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial
T I Chang, S Abdalla, G M London, et al.
JAMA
|
July 9, 2004
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
John L Petersen, Kenneth W Mahaffey, Vic Hasselblad, et al.
American Heart Journal
|
December 13, 2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
Harvey D White, Neal S Kleiman, Kenneth W Mahaffey, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial
Patrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
The New England Journal of Medicine
|
September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Lars Wallentin, Richard C Becker, Andrzej Budaj, et al.
Circulation
|
February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)
Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
American Heart Journal
|
December 9, 2019
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation
Sean D Pokorney, DaJuanicia N Holmes, Peter Shrader, et al.
American Heart Journal
|
January 2, 2022
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018
Abhinav Sharma, Kenneth W Mahaffey, Charles Michael Gibson, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF
Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Page
of 63
Search research articles
Search
Showing results (451-460 of 627) with videos related to
Sort By:
Page
of 63
The American Journal of Cardiology
|
July 14, 2022
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)
Rubina Attar, Angie Wu, Daniel Wojdyla, et al.
Journal of Human Hypertension
|
June 5, 2015
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial
T I Chang, S Abdalla, G M London, et al.
JAMA
|
July 9, 2004
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
John L Petersen, Kenneth W Mahaffey, Vic Hasselblad, et al.
American Heart Journal
|
December 13, 2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
Harvey D White, Neal S Kleiman, Kenneth W Mahaffey, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial
Patrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
The New England Journal of Medicine
|
September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Lars Wallentin, Richard C Becker, Andrzej Budaj, et al.
Circulation
|
February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)
Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
American Heart Journal
|
December 9, 2019
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation
Sean D Pokorney, DaJuanicia N Holmes, Peter Shrader, et al.
American Heart Journal
|
January 2, 2022
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018
Abhinav Sharma, Kenneth W Mahaffey, Charles Michael Gibson, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF
Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Page
of 63